The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia |
| |
| Affiliation: | 1. Division of Hematologic Malignancies, Department of Oncology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY;2. Department of Molecular & Developmental Biology, Albert Einstein College of Medicine, Bronx, NY;1. Regulation of Iron Metabolism Unit-Div. Genetics & Cell Biology-IRCCS San Raffaele Scientific Institute, Milano, Italy;2. San Raffaele Vita-Salute University, Milano, Italy;1. Department of Pediatric Hematology, Oncology and Immunology - University of Heidelberg, Heidelberg, Germany.;2. Molecular Medicine Partnership Unit, EMBL and University of Heidelberg, Heidelberg, Germany. |
| |
| Abstract: | Mutations in the group of epigenetic modifiers are the largest group of mutated genes in Myelodysplastic Syndromes (MDS) and are very frequently found in Acute Myeloid Leukemia (AML). Our advancements in the understanding of epigenetics in these diseases have helped develop groundbreaking therapeutics that have changed the treatment landscape of MDS and AML, significantly improving outcomes. In this review we describe the most common epigenetic aberrations in MDS and AML, and current treatments that target mutations in epigenetic modifiers, as well as novel treatment combinations, from standard therapies to investigational treatments. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
